The carboxy-terminal region of protein S has been recently been observed to be involved in the interaction between protein S and C4b-binding protein (Walker, F. J. 1989. J. Biol. Chem. 264:17645-17658 
Introduction
Protein C is a vitamin K-dependent protein found in the blood plasma. It can be converted to its active form, activated protein C by thrombin, when in complex with the endothelial cell surface protein thrombomodulin (1) . Activated protein C is a serine protease that has both anticoagulant (2-4) and profibrinolytic activities (4, 5) . Its anticoagulant activity is through the proteolytic inactivation of activated factor V (2, 6, 7) and factor VIII (7) (8) (9) . Proteolysis of factors V and VIII takes place on membranes, and maximum activity of activated protein C requires the presence of a cofactor, protein S (10). Protein S, also a vitamin K-dependent protein, has been isolated from human, bovine, and rabbit plasma (1 1-14) . Protein S has been shown to enhance the rate of inactivation of both factors V (10, 15) and VIII (9, 16) by activated protein C. Species specificity of the anticoagulant activity of activated protein C was first documented in 1972 (17) and was later shown to be due to its interaction with protein S (18) .
Protein S is unique in the family of vitamin K-dependent proteins because it is a cofactor rather than a zymogen of a serine protease. The amino acid sequences of bovine (19) and human (20) protein S have carboxy-terminal regions homologous to rat androgen-binding protein rather than the trypsinlike domains found in the other vitamin K-dependent proteins (21). Protein S activity in humans appears to be regulated by a unique mechanism. It does not require activation for expression of its anticoagulant cofactor activity as the single chain form found in plasma is active. In human blood, 40% of the protein S is found in complex with C4b-binding protein (22) . When in complex with this protein, protein S is unable to act as a cofactor for activated protein C (23). On the other hand, bovine protein S circulates primarily as free protein S because bovine C4b-binding protein does not interact strongly with protein S (23). Bovine blood contains another protein S binding protein which appears to enhance the anticoagulant activity of bovine protein S (24). The regulation of protein S in other species is unknown.
Recently, a synthetic peptide corresponding to a portion of protein S that is homologous to androgen binding protein has been found to interfere with the interaction between human protein S and C4b-binding protein, resulting in enhancement ofthe anticoagulant activity ofactivated protein C (25). To test the significance of this observation in vivo, we developed a rabbit model in which purified rabbit protein C and protein S have been employed to ensure that species specificity did not affect the results. In this paper, the role of protein S in the regulation of the rabbit protein C anticoagulant pathway is described and the effect on coagulation of perturbation of the protein S/C4b-binding protein interaction by a synthetic peptide in vivo is investigated.
Methods
Preparation of proteins. Rabbit protein C was purified either by a method previously described (14) or by immunoaffinity chromatogra-phy using the monoclonal antibody PC121 coupled to agarose. Human protein C (26) and bovine protein C (6) were prepared using previously described methods. Protein C was activated using the specific protein C activator isolated from the venom of Agkistrodon contortrix contortrix as described previously (27) . Bovine (10) and rabbit (14) protein S were purified using previously described methods. Bovine factor X was prepared according to the method described by Stenflo (28) and activated as described previously (29) . Human C4b-binding protein was purified according to the method of Dahlback (30). Protein S which was bound to the C4b-binding protein was removed by gel filtration in 3 M NaSCN buffered with 0.02 M Tris-HCl pH 7.5. Thiocyanate was removed from the C4b-binding protein by gel filtration.
Protein S was radiolabeled by the chloramine T method (31) . Radiolabeled protein S had a specific activity of 2,000 cpm/ng and retained anticoagulant cofactor activity. When radiolabeled rabbit protein S was electrophoresed in a 10% SDS-PAGE followed by autoradiography, a closely spaced doublet at 62,000 kD was seen that was similar to the pattern of unlabeled rabbit protein S (14) .
Synthetic peptides. The (33) .
Anticoagulant assay. The anticoagulant activity of activated protein C was measured by a method reported earlier (34) in which the effect of activated protein C on factor Xa-initiated clotting of rabbit plasma was determined by comparing the clotting time in the presence or absence of activated protein C. Briefly, 100 ul of bovine brain phospholipids (0.5 mg/ml) diluted in 0.02 M Tris HCI, 0.10 M NaCl, 1 mg/ml BSA, pH 7.5 (TBSA), 100 ,ul of bovine factor Xa diluted in TBSA, and 100 zd of rabbit plasma were incubated at 37°C for 2 min. 5 il ofactivated protein C was added and clotting initiated by adding 100 ,LI of 0.025 M CaCI2. A standard curve was prepared using serial dilutions of bovine factor Xa and the anticoagulant effect defined as "percent inhibition of factor Xa activity." The ability of rabbit protein S to serve as a cofactor for the anticoagulant activity of rabbit protein C was tested using a modification of the above assay, as described earlier (34). Briefly, bovine plasma was used in place of rabbit plasma and 10 ,u of samples to be tested for protein S activity were also added.
Determination offree protein S. The concentration of free protein S was measured in one of three ways. In the first method ("PEG precipitation") '251-labeled protein S (10 ng/ml final concentration) was added to plasma in the presence or absence of synthetic peptides and incubated at 37°C for 2 h. A 25% solution of polyethylene glycol 8000 (PEG 8000) was added to a final concentration of 6%, the samples mixed and incubated on ice for 30 min, and the precipitate removed by centrifugation in a microfuge (Beckman Instruments, Inc., Fullerton, CA) at full speed for 5 min. A sample was removed from the supernatant and counted in a gamma counter. Although 3-4% PEG is used to measure the concentration of free protein S in human plasma, precipitation with 6% PEG was chosen on the basis of the following observation. Various concentrations of PEG were added to rabbit plasma, the mixtures were centrifuged, and the supernatants were electrophoresed on agarose gels. Autoradiography of the gels revealed that the 6% PEG supernatant contained free protein S but not the high-molecular weight protein S/C4b-binding protein complex (data not shown).
Alternatively, 25 All of 125I rabbit protein S was added to 475 Al of rabbit plasma, and, after incubation at 37°C for 2 h, the sample gel filtered over a 0.9 x 55 cm column of Ultragel ACA 34 as described by Dahlback (22) . As (35) . Samples of plasma in the presence or absence of synthetic peptides were first electrophoresed in 1% agarose in 0.08 M Tris base, 0.024 M tricine, pH 8.6, with 0.3 mM EDTA-Na4 (tricine buffer). The second-dimension gel contained 1% guinea pig anti-rabbit protein S in tricine buffer.
Electrophoresis. Purity of proteins was assured by electrophoresis in SDS-PAGE according to Laemmli (36) . Flat bed agarose electrophoresis was carried out by modifications of the method of Jeppson, as described by Dahlback (22) . Gels were stained either with Coomassie brilliant blue or with silver nitrate (37) .
Western immunoblotting. After SDS-PAGE, samples were electroblotted onto nitrocellulose for 1 h on a Jannsen semidry blotter. After blocking with 5% Carnation Instant Milk, the blot was incubated overnight with guinea pig antibodies to rabbit protein C or protein S. Peroxidase-conjugated goat anti-guinea pig IgG antibodies were added for an additional 4 h and the blot developed with 4 chloro-l-naphthol. The blots were washed three times with 0.02 M Tris-HCl, 0.10 M NaCI, pH 7.5, before and after incubation with the second antibody.
Autoradiography. Samples containing '25I rabbit protein S were subjected to electrophoresis on agarose or SDS-PAGE, the gels dried and incubated at -70°C with Kodak X-omat AR film, and the film developed using standard methods.
Animal studies. Male New Zealand White rabbits weighing between 3 and 5 kg were received from a single supplier and housed at the Center for Laboratory Animal Care at the University of Connecticut Health Center. Clearance ofbovine protein S was measured after intravenous infusion of 1251 bovine protein S via the marginal ear vein of a rabbit lightly sedated with ketamine HCl. Serial blood samples were collected in plastic syringes containing 3.8% sodium citrate (1:9 vol/ vol) from an indwelling catheter in the contralateral ear artery, immediately centrifuged to obtain plasma, and radioactivity measured in a gamma counter. Clearance of the synthetic peptides GVQLDLDEAI and PINPRLDG was determined after intravenous injection of fluorescein-labeled peptide. Blood samples were obtained as described above and plasma immediately prepared by centrifugation. Plasma samples were analyzed by spectrofluorometry using a model 8000 spectrofluorometer (SLM Instruments Inc., Urbana, IL). Emission at 515 nm was measured (with appropriate blanks) after excitation at 492 nm. The anticoagulant activity of exogenously added rabbit activated protein C and the concentration of free protein S were determined as described previously in plasma samples obtained from rabbits after administration of the synthetic peptides.
Statistical analysis. Slopes of lines were calculated using power regression analysis according to standard methods. Comparison of matched samples was accomplished by using Student's t test.
Results
Characterization of rabbit protein C anticoagulant activity. Rabbit protein C, like the human and bovine proteins, is a two-chain protein (14) . After conversion to its active form, activated protein C, it is able to cleave small synthetic chromogenic substrates (14) and possesses potent anticoagulant activity in rabbit plasma (Fig. 1, bar 1) . The anticoagulant activity of rabbit activated protein C is species specific because rabbit activated protein C has little activity in bovine plasma (Fig. 1, bar 2) .
Rabbit protein S is a single-chain protein (14) and possesses no inherent protease activity (data not shown). How ever, because addition of rabbit protein S to bovine plasma imparts anticoagulant activity to rabbit activated protein C (Fig. 1, bars 3-6 ), it appears that rabbit protein S is a cofactor for expression of the anticoagulant activity of rabbit activated protein C. Because human and bovine activated protein C have little anticoagulant activity in rabbit plasma (Fig. 2 ), it appears that rabbit protein S cannot act as a cofactor for the expression of anticoagulant activity by activated protein C of heterologous species. Thus, the anticoagulant activity of both rabbit activated protein C and protein S are species specific.
Although the formation of a protein S/C4b-binding protein complex is felt to be important in the regulation of the anticoagulant cofactor activity of human protein S, the ratio of free to bound protein S in other animals is variable. For example, there is very little bound protein S in bovine plasma (23). To investigate the importance of this interaction in rabbit plasma, 125I-labeled rabbit protein S was added to rabbit plasma and the mixture then gel filtered over a column of Ultragel ACA 34. The radioactivity of the column fractions was measured and two major peaks were observed (Fig. 3 A) , a pattern very similar to that reported in human plasma (23).
When samples taken from the individual column fractions were subjected to 6% native gel electrophoresis and subsequent autoradiography, the first peak was found to correspond to a very high-molecular weight band consistent with a protein S/C4b-binding protein complex and the second peak to a smaller protein consistent with free protein S (Fig. 3 B) . A third peak that followed just behind that of free protein S appears to be comprised of a small (-25-kD) protein. This is believed to result from proteolytic degradation of protein S during iodination and was variably present. 125I-labeled rabbit protein S alone eluted in a single peak corresponding to free protein S (Fig. 3 A, dotted line) . Thus, the high-molecular weight complex results from an interaction between rabbit protein S and a plasma protein rather than aggregates of rabbit protein S. This data suggests that rabbit protein S forms a complex with rabbit C4b-binding protein.
Modildation of protein S activitY in vitro. The peptide GVQLDLDEAI, which corresponds to amino acids 605-614 of the human protein S sequence, has been found to interfere with the protein S/C4b-binding protein interaction in human plasma (25). Because rabbit protein S has been found to have anticoagulant cofactor activity and appears to form a complex with rabbit C4b-binding protein, it was postulated that if GVQLDLDEAI were to affect the protein S/C4b-binding protein interaction it would alter the anticoagulant cofactor activity of rabbit protein S. GVQLDLDEAI was found to enhance the anticoagulant activity of exogenously added rabbit activated protein C (Fig. 4) . The effect was dose-dependent with a half-maximal effect of -5 ,M. Neither DGEQLADLIV (scrambled amino acids 605-614) nor PINPRLDG, which corresponds to amino acids 400-407 of the human protein S sequence, had any effect. Addition of GVQLDLDEAI had no effect on factor Xa activity in the absence of activated protein C (Fig. 4) , indicating that its action was mediated by an effect on protein C anticoagulant activity rather than via a direct effect on coagulation. In the absence of added C4b-binding protein, 8 ,uM and 42 AiM GVQLDLDEAI increased the anticoagulant activity of rabbit activated protein C in rabbit plasma from 37.6 to 50.37% (P < 0.02) and 61.67% (P < 0.02), respectively. Addition of exogenous C4b-binding protein (human or rabbit) blocked this effect (Fig. 5 ). This data supports a mechanism of action involving protein S rather than a direct effect of GVQLDLDEAI on activated protein C. The effect of GVQLDLDEAI on the distribution of rabbit protein S was then studied to further define its effect in rabbit plasma. When the distribution of free and bound 1251 protein S was determined by PEG precipitation, addition of GVQLDLDEAI was noted to cause an increase in the relative concentration of free protein S in a dose-dependent fashion (Fig. 6 ). The half-maximal effect of the peptide (5-10 ,uM) was very similar to that noted for its effect on coagulation. In addition, addition of GVQLDLDEAI to rabbit plasma decreased the concentration of protein S bound to C4b-binding protein from 45 .7±2.0% to 36.3±1.98% of total protein S (P < 0.02) when the distribution of protein S was measured by gel filtration (Fig. 7, A and B phoresis the relative proportion of free protein S (indicated by the arrows) was increased in plasma samples containing GVQLDLDEAI (Fig. 7, C and D Fig. 8) . However, the clearance of GVQLDLDEAI was much less rapid than that ofthe similarly sized peptides PINPRLDG and DGEQLADLIV (half-lifes of 15 min; Fig. 8 ). The clearance of GVQLDLDEAI appeared to be biphasic with an initial phase of rapid clearance (half-life of 15-18 min) followed by a second phase in which clearance was slower. The rates of clearance did not vary when the dose of peptide infused was varied from 12.5 to 50 ,g/ml (data not shown). Although the reason for this difference is not readily apparent, one might expect that the clearance of GVQLDLDEAI bound to C4-binding protein would be reduced. Regardless, the clearance of GVQLDLDEAI is slow enough to allow the attainment of plasma levels comparable to those used in the in vitro studies.
Plasma samples obtained from rabbits after infusion with varying doses of GVQLDLDEAI exhibited an enhanced anticoagulant response to rabbit activated protein C (Fig. 9) . This effect was found to be dose-dependent and half-maximal stimulation occurred at a peptide concentration of 5 ,uM (in good agreement with the effect seen in vitro). There was no effect on factor Xa-initiated coagulation if activated protein C was not added, suggesting that administration of GVQLDLDEAI did not have a direct effect on coagulation. Infusion of a rabbit with PINPRLDG did not result in any enhancement ofanticoagulation (Fig. 9) . In addition, the relative concentrations of free protein S were determined by gel filtration in plasma samples taken from rabbits after administration of GVQLDLDEAI and in samples taken from the same animals before the infusion. The percentage of protein S bound to C4b-binding protein decreased from 35.3 to 23.3% 6 min after infusion with 10 mg of GVQLDLDEAI (corresponding to a plasma concentration of 31 ,uM). After 20 min (plasma concentration of 17 qM), the percentage of protein S in the highmolecular weight complex rose to 29.9%. These results suggest that GVQLDLDEAI interferes with the protein S-C4b-binding protein interaction in vivo and increases the anticoagulant cofactor activity of rabbit protein S.
Discussion
The protein C pathway is felt to be an important element in the regulation of blood coagulation. Hereditary deficiencies of both protein C (38, 39) and protein S (40, 41) have been described in association with a predisposition to thrombotic events. The importance ofthe formation ofa complex between protein S and C4b-binding protein is underscored by the report of a variant of protein S deficiency in which nearly all of the protein S was found to be bound to C4b-binding protein, resulting in low levels of free protein S and a thrombotic diathesis (35) . The recent identification of a domain of protein S that appears to be involved with its interaction with C4b-binding protein (25) suggested a means by which one may test the hypothesis that the protein S/C4b-binding protein interaction plays a role in the regulation of coagulation in vivo.
It was necessary to consider several factors in the design of an animal model. To assess the importance of the protein S/C4b-binding protein interaction in vivo, the following conditions must be met: (a) Protein S in that animal must function as a cofactor for activated protein C. (b) Protein S must bind to C4b-binding protein. (c) GVQLDLDEAI must be able to displace protein S from C4b-binding protein. The structure and function of protein S has been well studied only in human and bovine plasma. Unfortunately, neither species is suitable for these in vivo studies. The peptide GVQLDLDEAI, which had been shown to enhance the anticoagulant activity of activated protein C in vitro in human plasma, had no effect in bovine plasma. The reason that the protein S/C4b-binding protein interaction is not important in the regulation ofbovine protein S is that bovine plasma contains very low concentrations of C4b-binding protein.
Rabbits were chosen for use in these in vivo studies because rabbit models have already been used to study the activation of coagulation in vivo in neoplasia (42, 43) or endotoxin shock (44, 45) , and thrombin activation of protein C (46, 47 and enhanced its anticoagulant cofactor activity in vitro, we concluded that there is cross-species homology between the regions involved in the binding of protein S to C4b-binding protein.
The results of the experiments conducted in the in vitro system indicated that the rabbit would be a good animal in which to study the interaction between protein S and C4b-binding protein in vivo. The major concern was that a small peptide such as GVQLDLDEAI would be cleared so rapidly from the circulation that effective plasma levels would not be achieved. Indeed, the control peptide PINPRLDG was cleared extremely rapidly (Fig. 8) . The clearance of GVQLDLDEAI, on the other hand, was sufficiently slow to allow the attainment of effective plasma levels for several hours after a single intravenous injection. The (48) . If infused concurrently with activated protein C in such a situation, the use of GVQLDLDEAI may reduce the dose of activated protein C needed to achieve anticoagulation. Alternatively, GVQLDLDEAI may be useful in situations, such as disseminated intravascular coagulation, in which endogenous activation of protein C may be elevated. Recently, activated protein C has been shown to provide protection against endotoxin shock in a primate model (49) . Use of GVQLDLDEAI, either alone or with activated protein C, may be of benefit in the treatment of sepsis in such a setting. The 
